-

Webinar - Phage therapy in agriculture: From discovery to field application

Thursday, 12th March, 4pm to 5pm (UK time) - in Microsoft Teams

Bacterial pathogens pose a major threat to global food security, ecosystems, and commercial agriculture, causing significant economic losses. In the UK, black rot in brassicas and bacterial canker in cherries severely affect vegetable and fruit production. As traditional chemical controls lose effectiveness and antimicrobial resistance rises, there is an urgent need for sustainable, targeted alternatives.

Bacteriophages (phages), naturally occurring viruses that infect and kill bacteria, offer a promising strategy for managing plant bacterial diseases. Unlike chemical treatments, phages can selectively eliminate pathogenic bacteria without harming beneficial microbes, preserving the plant microbiome. Effective phage-based control relies on isolating and characterising phages, understanding their infection dynamics, and assessing their ability to suppress disease within plant tissues and natural environments. Knowledge of the genetic mechanisms underlying phage-bacterial interactions is essential for designing phage cocktails capable of targeting diverse pathogenic strains. Dr Mojgan Rabiey investigates the potential of phage-based strategies to provide precise, sustainable, and environmentally friendly solutions for controlling bacterial diseases in agriculture.

Click here to register : https://warwick.ac.uk/fac/sci/lifesci/wcc/latestnews/webinars/mojgan/

Dr Mojgan Rabiey


Comments

Post a Comment

Popular posts from this blog

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more